Sogawa Kazuyuki, Yamanaka Sakino, Takano Shigetsugu, Sasaki Kosuke, Miyahara Yoji, Furukawa Katsunori, Takayashiki Tsukasa, Kuboki Satoshi, Takizawa Hirotaka, Nomura Fumio, Ohtsuka Masayuki
Department of Biochemistry, School of Life and Environmental Science, Azabu University, Sagamihara, Kanagawa 252-5201, Japan.
Department of General Surgery, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
Oncol Lett. 2021 Feb;21(2):127. doi: 10.3892/ol.2020.12388. Epub 2020 Dec 17.
C4b-binding protein α-chain (C4BPA) was previously identified as a novel serum biomarker for pancreatic ductal adenocarcinoma (PDAC). To apply this biomarker for clinical diagnosis, a lectin ELISA was established to measure serum fucosylated (Fuc)-C4BPA levels in 45 patients with PDAC, 20 patients with chronic pancreatitis (CP) and 50 healthy volunteers (HVs) in one training and three validation sets. The lecithin ELISA developed in the current study exhibited satisfactory within-run (2.6-6.7%) and between-day (1.8-3.6%) coefficient of variations. Serum Fuc-C4BPA levels in patients with PDAC (0.54±0.27 AU/ml) was significantly higher than that in HVs (0.21±0.06 AU/ml; P<0.0001) and patients with CP (0.25±0.03 AU/ml; P<0.0001). Additionally, serum Fuc-C4BPA levels in preoperative patients were significantly decreased compared with postoperative patient sera (P<0.0003). The receiver operating characteristic (ROC) curve analyses revealed that the area under the curve (AUC) of Fuc-C4BPA (0.985) was higher than that of carbohydrate antigen (CA)19-9 (0.843), carcinoembryonic antigen (0.548) and total C4BPA (0.875) (P<0.001). To analyze the clinical significance of Fuc-C4BPA, the ability of Fuc-C4BPA to predict lymph node metastasis was compared with that of CA19-9. The AUC of serum Fuc-C4BPA levels (0.703) was significantly higher than that of serum CA19-9 levels (0.500) in patients with PDAC (P<0.001). The current study established a novel lectin ELISA for measuring serum Fuc-C4BPA levels. Thus, Fuc-C4BPA has potential clinical applications owing to its high diagnostic value in PDAC.
C4b结合蛋白α链（C4BPA）先前被鉴定为胰腺导管腺癌（PDAC）的一种新型血清生物标志物。为了将该生物标志物应用于临床诊断，建立了一种凝集素酶联免疫吸附测定法（lectin ELISA），以测量45例PDAC患者、20例慢性胰腺炎（CP）患者和50名健康志愿者（HV）在一个训练集和三个验证集中的血清岩藻糖基化（Fuc）-C4BPA水平。本研究开发的凝集素酶联免疫吸附测定法在批内变异系数（2.6-6.7%）和日间变异系数（1.8-3.6%）方面表现令人满意。PDAC患者的血清Fuc-C4BPA水平（0.54±0.27 AU/ml）显著高于HV（0.21±0.06 AU/ml；P<0.0001）和CP患者（0.25±0.03 AU/ml；P<0.0001）。此外，术前患者的血清Fuc-C4BPA水平与术后患者血清相比显著降低（P<0.0003）。受试者工作特征（ROC）曲线分析显示，Fuc-C4BPA的曲线下面积（AUC）（0.985）高于糖类抗原（CA）19-9（0.843）、癌胚抗原（0.548）和总C4BPA（0.875）（P<0.001）。为了分析Fuc-C4BPA的临床意义，将Fuc-C4BPA预测淋巴结转移的能力与CA19-9进行了比较。在PDAC患者中，血清Fuc-C4BPA水平的AUC（0.703）显著高于血清CA19-9水平的AUC（0.500）（P<0.001）。本研究建立了一种用于测量血清Fuc-C4BPA水平的新型凝集素酶联免疫吸附测定法。因此，Fuc-C4BPA因其在PDAC中的高诊断价值而具有潜在的临床应用价值。
